Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring

BACKGROUND: Serum drug-level assays for infliximab (IFX) and adalimumab (ADA) are widely available and are most often obtained reactively, to determine the next steps in patients with loss of response. Studies done thus far on the use of these assays proactively, or during symptom remission, have ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Syed, Nauroz, Tolaymat, Mazen, Brown, Sara A, Sivasailam, Barathi, Cross, Raymond K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380488/
https://www.ncbi.nlm.nih.gov/pubmed/32743546
http://dx.doi.org/10.1093/crocol/otaa050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380488/
https://www.ncbi.nlm.nih.gov/pubmed/32743546
http://dx.doi.org/10.1093/crocol/otaa050

Ejemplares similares